Survey on the awareness and clinical application of guidelines for the prevention and treatment of chronic hepatitis B （2022 edition） among clinicians

Yuanyuan KONG; Yujie GUO; Yujuan GUAN; Xuan LIANG; Zhongjie HU; Xiaobo LU; Mingqin LU; Yongfeng YANG; Meifang HAN; Hong YOU; Zhiyun YANG; Jidong JIA

Return

Survey on the awareness and clinical application of guidelines for the prevention and treatment of chronic hepatitis B （2022 edition） among clinicians

VernacularTitle:临床医生对《慢性乙型肝炎防治指南（2022年版）》认知与实践情况的调查
Author: Yuanyuan KONG ¹ ; Yujie GUO ² ; Yujuan GUAN ³ ; Xuan LIANG ⁴ ; Zhongjie HU ⁵ ; Xiaobo LU ⁶ ; Mingqin LU ⁷ ; Yongfeng YANG ⁸ ; Meifang HAN ⁹ ; Hong YOU ¹ ; Zhiyun YANG ² ; Jidong JIA ¹
Author Information

1. Beijing Friendship Hospital， Capital Medical University， Beijing 100050， China
2. Beijing Ditan Hospital， Capital Medical University， Beijing 100015， China
3. Guangzhou Eighth People’s Hospital， Guangzhou Medical University， Guangzhou 510440， China
4. The Sixth People’s Hospital of Shenyang， Shenyang 110006， China
5. Beijing YouAn Hospital， Capital Medical University， Beijing 100069， China
6. The First Affiliated Hospital of Xinjiang Medical University， Urumqi 830054， China
7. The First Affiliated Hospital of Wenzhou Medical University， Wenzhou， Zhejiang 325000， China
8. Nanjing Second Hospital， Nanjing 211103， China
9. Tongji Hospital， Tongji Medical College of Huazhong University of Science and Technology， Wuhan 430030， China
Publication Type:Journal Article
Keywords: Hepatitis B， Chronic; Diagnostic and Treatment Guideline; Surveys and Questionnaires
From: Journal of Clinical Hepatology 2025;41(6):1068-1074
CountryChina
Language:Chinese
Abstract: ObjectiveTo investigate the awareness and clinical practice of guidelines for the prevention and treatment of chronic hepatitis B （2022 edition） among clinicians. MethodsFrom July 19 to December 31， 2024， a self-designed electronic questionnaire was distributed via the WeChat mini program to collect related data from 1 588 clinicians nationwide， including their awareness and practice based on 18 questions regarding testing and referral， diagnosis and treatment， and follow-up. ResultsAmong all respondents， only 350 clinicians correctly understood all the updated key points of antiviral indications and treatment for special populations in the 2022 edition of guidelines for the prevention and treatment of chronic hepatitis B， with an overall awareness rate of 22.0%. Only 20% ‍—‍ ‍40% of the patients with positive HBV DNA and an age of >30 years receive antiviral therapy， while 80% ‍—‍ ‍100% of the patients with positive HBV DNA and a family history of hepatitis B cirrhosis or hepatocellular carcinoma receive antiviral therapy. The median follow-up rates at 1 year， 3 years， and 5 years were 67.5% 57.5% and 47.5%，respectively， showing a trend of gradual reduction， which might be associated with the influencing factors such as insufficient time for follow-up management by clinicians， insufficient awareness of the disease among patients， and poor adherence to follow-up. ConclusionThere is a gap between the awareness and practice of guidelines for the prevention and treatment of chronic hepatitis B （2022 edition） among clinicians. It is recommended to further strengthen training and focus on the whole process of “detection， diagnosis， treatment， and management” for patients with chronic hepatitis B in healthcare institutions， in order to promote the implementation of the guidelines.